 | | Vol. 5.00 – 8 January, 2021 |
| |
|
|
| Researchers examined the mechanism how reduction of TIF1γ in hepatic stellate cells (HSCs) induced damage on hepatocytes and liver fibrosis. HSCs were isolated from mice liver and the role of Tif1γ was analyzed.
[Cell and Bioscience] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators explored the potential role of PDLIM2 in the development and epithelial-mesenchymal transition of hepatocellular carcinoma via a possible modulation of β-catenin.
[Cancer Gene Therapy] |
|
|
|
| Scientists demonstrated that exosomal LINC00161 derived from hepatocellular carcinoma (HCC)-cells were significantly associated with enhanced proliferation, migration, and angiogenesis in HUVECs in vitro, all of which were effectively inhibited when LINC00161 was spliced with shRNA in HCC-cells.
[Cancer Gene Therapy] |
|
|
|
| The authors reported a unique histological structure termed “crown-like structure”, where liver-resident macrophages surrounded dead hepatocytes, scavenged their debris, and induced inflammation and fibrosis in nonalcoholic steatohepatitis (NASH).
[iScience] |
|
|
|
| Investigators assessed the effectiveness of hypermethylation at the CpG island of ZNF154, a previously reported multi-cancer specific signature for use in a blood-based cancer detection assay.
[Scientific Reports] |
|
|
|
| Scientists investigated the impact of chemotherapy on the tumor immune microenvironment. They treated human liver metastases slices with 5-fluorouracil plus either irinotecan or oxaliplatin, then performed single-cell transcriptome analyses.
[Cell Reports Medicine] |
|
|
|
| Red betel leaves extract (RBLE) protective effect against APAP-induced HepG2 cells was determined. APAP-induced HepG2 as hepatotoxicity cell model was treated with RBLE at 25 and 100 μg/mL.
[Heliyon] |
|
 |
|
|
|
| The authors discuss the recent advances in the understanding of the molecular mechanisms involved in vitamin D and its receptor signaling and how genetic variants influence inflammatory responses and fibrogenic outcomes.
[Hepatology] |
|
|
|
|
| Metacrine, Inc. announced that the first patient has been treated in the company’s Phase IIa trial evaluating MET409 in combination with empagliflozin, a sodium-glucose cotransport-2 inhibitor, in patients with both type II diabetes mellitus and nonalcoholic steatohepatitis.
[Metacrine, Inc.] |
|
|
|
| University of Florida Health researchers have been awarded a $2.3 million National Institutes of Health grant to screen more than 1,000 patients at health center outpatient clinics over the next two-and-a-half years to determine the pervasiveness of liver scarring from inflammation caused by a fatty liver.
[University of Florida Health] |
|
|
|
|
| January 25 – 28, 2021
Virtual |
|
|
|
|
|
| | STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| | Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
| | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
